Apellis Pharmaceuticals, Inc.
APLSNASDAQHealthcare
$41.03
+$0.00(+0.00%)
Market Cap$5.3B
P/E Ratio—
52W High$41.14
52W Low$16.61
Apellis Pharmaceuticals, Inc.（APLS）· 资产负债表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · APLS · 截至 2026-06-10
财务报表
Total Assets · Total Liabilities · Equity
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & ST Investments | $0.47B | $0.42B | $0.35B | $0.55B | $0.70B |
| Net Receivables | $0.37B | $0.27B | $0.21B | $0.01B | $0.08B |
| Inventory | $0.14B | $0.08B | $0.15B | $0.09B | $0.02B |
| Total Current Assets | $1.01B | $0.79B | $0.77B | $0.72B | $0.82B |
| PP&E Net | $0.02B | $0.02B | $0.02B | $0.02B | $0.03B |
| Goodwill | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Intangible Assets | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Assets | $1.08B | $0.89B | $0.79B | $0.76B | $0.88B |
| Liabilities | |||||
| Short-Term Debt | $0.10B | $0.00B | $0.00B | $0.00B | $0.00B |
| Accounts Payable | $0.06B | $0.04B | $0.04B | $0.04B | $0.02B |
| Total Current Liabilities | $0.32B | $0.19B | $0.25B | $0.17B | $0.13B |
| Long-Term Debt | $0.37B | $0.45B | $0.09B | $0.09B | $0.19B |
| Total Liabilities | $0.71B | $0.66B | $0.59B | $0.59B | $0.68B |
| Stockholders Equity | |||||
| Retained Earnings | ($3.01B) | ($3.04B) | ($2.84B) | ($2.31B) | ($1.66B) |
| Total Stockholders Equity | $0.37B | $0.23B | $0.19B | $0.17B | $0.20B |
| Total Liab & Equity(computed) | $1.08B | $0.89B | $0.79B | $0.76B | $0.88B |
| Debt Summary | |||||
| Total Debt | $0.49B | $0.47B | $0.11B | $0.11B | $0.21B |
| Net Debt | $0.02B | $0.06B | ($0.24B) | ($0.44B) | ($0.43B) |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · B
深入了解Apellis Pharmaceuticals, Inc.
关于Apellis Pharmaceuticals, Inc.（APLS）资产负债表
Apellis Pharmaceuticals, Inc.总资产$1.08B，现金及短期投资$0.47B，总负债$0.71B，总债务$0.49B，股东权益$0.37B。
常见问题
APLS · 4 问Apellis Pharmaceuticals, Inc.总债务$0.49B，净债务$0.02B。
APLS total debtnet debtdebt to equity
· Source: FMP /stable/balance-sheet-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10